New eyedrop shows promise for pink eye in small trial
NCT ID NCT05356793
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new anti-infective eyedrop called SCH1 in 30 adults with acute infectious conjunctivitis (pink eye). Participants received either the active eyedrop or a placebo. The goal was to see if the drug could completely clear redness and discharge. The trial is complete, and results are being analyzed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SCH-1 eyedrop (novel anti-infective)
- What this could lead to
- If successful, this could provide a new treatment option for pink eye, potentially reducing symptoms faster than current care.
- What could go wrong
- This is a small, early-phase trial with only 30 participants. The results may not apply to everyone, and the drug may not prove more effective than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE INFECTIOUS CONJUNCTIVITIS (DISORDER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jacqueline Dauhajre, MD
Jackson Heights, New York, 11372, United States